Illinois Bill Regarding Vaccines Derived from Aborted Fetal Tissue (HB 342)
This law was last updated on May 2, 2019
This law is Anti–Choice
Number
HB 342
Status
Proposed
Proposed
Jan 11, 2019
Sponsors
Primary Sponsors: 1
Co-sponsors: 1
Total Sponsors: 2
Full Bill Text
HB 342 would require the health department to create and maintain a list of each immunizing agent derived from aborted fetal tissue. The list would also need to include any immunizing agents that are not derived from aborted fetal tissue which can be used as alternatives.
The bill defines “immunizing agent derived from aborted fetal tissue” to mean:
An immunizing agent that is manufactured using a human fetal or embryonic cell line, protein, deoxyribonucleic acid, recombinant deoxyribonucleic acid, monoclonal antibody, or any other component derived from an elective abortion or using a cell line derived from the tissue of a fetus that was electively aborted.
When providing vaccines, a health-care provider would be required to notify the patient if the immunizing agent is derived from aborted fetal tissue, and if available, offer an alternative vaccine which does not derive from aborted fetal tissue.
Related Legislation
Identical to Michigan’s SB 1005, which failed to pass in 2018.
Latest Action
1/11/19 – Filed.
People
Primary Sponsor
Co-sponsor
Latest on Rewire News Group
